Mastodon

Aminomethylbenzoic acid (Solution) Instructions for Use

Marketing Authorization Holder

Pharmazashchita SPC, FSUE FMBA of Russia (Russia)

ATC Code

B02AA03 (Aminomethylbenzoic acid)

Active Substance

Aminomethylbenzoic acid (Ph.Eur. European Pharmacopoeia)

Dosage Form

Bottle Rx Icon Aminomethylbenzoic acid Solution for intravenous and intramuscular administration 10 mg/1 ml: 5 ml amp. 10, 20, 50 or 100 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration colorless, transparent.

1 ml 1 amp.
Aminomethylbenzoic acid (calculated as the anhydrous substance) 10 mg 50 mg

Excipients: sodium chloride – 9 mg, water for injections – up to 1 ml.

5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (4) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (10) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (20) – cardboard packs.

Clinical-Pharmacological Group

Hemostatic agent. Fibrinolysis inhibitor – inhibitor of plasminogen to plasmin conversion

Pharmacotherapeutic Group

Hemostatic agents; antifibrinolytic agents; amino acids

Pharmacological Action

Antifibrinolytic agent, a derivative of aminocaproic acid. It has a hemostatic effect by competitively inhibiting enzymes – kinases (plasmic, tissue, streptokinase) that activate the conversion of profibrinolysin (plasminogen) to fibrinolysin (plasmin).

Pharmacokinetics

After oral administration, Aminomethylbenzoic acid is detected in the blood after 15 minutes. Cmax is reached after 3 hours. After intramuscular injection, Aminomethylbenzoic acid undergoes rapid resorption, Cmax in the blood is reached after 30-60 minutes.

After intravenous injection of the drug at a dose of 1.5 mg/kg, the concentration of aminomethylbenzoic acid in the blood decreases rapidly and after 3 hours reaches a level where the active substance is practically undetectable.

Aminomethylbenzoic acid is excreted by the kidneys through glomerular filtration and tubular secretion, with 50-60% excreted unchanged.

Indications

Local bleeding due to increased fibrinolysis in surgical, urological, and gynecological practice; generalized fibrinolytic bleeding (including during fibrinolytic therapy, during operations on the organs of the thoracic and abdominal cavities; in prostate cancer; in leukemia; in obstetric practice with delayed postpartum uterine involution, after medical abortion, after manual separation of the placenta, in intrauterine fetal death, amniotic fluid embolism).

ICD codes

ICD-10 code Indication
R58 Hemorrhage, not elsewhere classified
T81.0 Haemorrhage and haematoma complicating a procedure, not elsewhere classified
ICD-11 code Indication
MG27 Hemorrhage, not elsewhere classified
NE81.0Z Hemorrhage or hematoma of other or unspecified sites complicating a procedure, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer the regimen intravenously or intramuscularly based on the clinical indication and severity of bleeding.

For intravenous administration, inject a single dose of 50-100 mg (1-2 ampoules) slowly over a period of at least 5 minutes.

For intramuscular administration, inject a single dose of 50-100 mg (1-2 ampoules) deeply into the muscle.

Repeat the administration 3-4 times daily or as clinically required to achieve hemostasis.

In obstetric practice, for postpartum hemorrhage, administer a dose of 100 mg (2 ampoules) intravenously, repeating if necessary based on clinical assessment.

For surgical procedures with a high risk of fibrinolytic bleeding, administer a dose of 100 mg (2 ampoules) intravenously prior to or during the intervention.

The maximum daily dose should generally not exceed 600 mg (12 ampoules).

Adjust the dosage and frequency based on coagulogram parameters and clinical response, particularly in patients with a predisposition to thrombosis.

In cases of hematuria, ensure adequate fluid intake and monitor diuresis to prevent the formation of blood clots in the urinary tract.

The duration of treatment is determined by the underlying condition and the achievement of stable hemostasis.

Adverse Reactions

From the digestive system: nausea, vomiting, diarrhea.

From the cardiovascular system: fluctuations in blood pressure, tachycardia.

From the central nervous system: dizziness.

Contraindications

Severe renal impairment, first trimester of pregnancy, hemorrhage into the vitreous body, hypercoagulable phase of consumption coagulopathy, hypersensitivity to aminomethylbenzoic acid.

Use in Pregnancy and Lactation

Contraindicated in the first trimester of pregnancy.

Can be used in obstetric practice according to indications.

Experimental studies have shown that Aminomethylbenzoic acid is a compound with low toxicity. No teratogenic effects or effects on the reproductive system were identified.

Use in late pregnancy and during breastfeeding is possible in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus or breastfed infant.

Use in Hepatic Impairment

Used for liver diseases according to indications.

Use in Renal Impairment

Contraindication: severe renal impairment.

When treating hematuria with aminomethylbenzoic acid, the formation of blood clots in the urinary tract is possible, which can lead to renal colic. Therefore, it is necessary to ensure sufficient fluid intake and monitor diuresis.

Geriatric Use

Use with caution due to the risk of adverse reactions and taking into account contraindications.

Special Precautions

Use with caution in patients with a predisposition to thrombosis. Treatment is carried out under the control of a coagulogram.

When treating hematuria with aminomethylbenzoic acid, the formation of blood clots in the urinary tract is possible, which can lead to renal colic. Therefore, it is necessary to ensure sufficient fluid intake and monitor diuresis.

Drug Interactions

Simultaneous use of aminomethylbenzoic acid in high doses and other hemostatic agents (for example, etamsylate) can lead to the formation of blood clots – on the one hand, due to increased fibrin formation under the influence of hemostatics, and on the other hand, due to the slow dissolution of clots due to the antiplasmin effect of aminomethylbenzoic acid.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS